Arrowhead Pharmaceuticals (ARWR) Now Covered by Analysts at B. Riley

B. Riley initiated coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report published on Friday, January 5th, Marketbeat reports. The firm issued a neutral rating and a $3.00 target price on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. BidaskClub raised shares of Arrowhead Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, December 27th. Cantor Fitzgerald set a $2.00 target price on shares of Arrowhead Pharmaceuticals and gave the stock a hold rating in a report on Tuesday, December 12th. Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. William Blair raised shares of Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a report on Monday, September 18th. Finally, Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 target price for the company in a report on Monday, November 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Arrowhead Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $3.13.

Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) traded up $0.68 on Friday, hitting $5.72. 7,343,700 shares of the stock were exchanged, compared to its average volume of 3,400,156. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $6.25. The company has a market cap of $428.02, a P/E ratio of -12.17 and a beta of 1.79. The company has a current ratio of 3.63, a quick ratio of 3.63 and a debt-to-equity ratio of 0.03.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative net margin of 109.46% and a negative return on equity of 38.10%. analysts expect that Arrowhead Pharmaceuticals will post -0.8 earnings per share for the current year.

In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction dated Monday, January 1st. The shares were sold at an average price of $3.69, for a total value of $73,800.00. Following the completion of the sale, the chief operating officer now owns 948,356 shares of the company’s stock, valued at approximately $3,499,433.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.57% of the company’s stock.

Several large investors have recently modified their holdings of the company. Allianz Asset Management GmbH acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $1,958,000. Dimensional Fund Advisors LP raised its position in shares of Arrowhead Pharmaceuticals by 252.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 31,765 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Arrowhead Pharmaceuticals by 10.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock valued at $742,000 after buying an additional 16,103 shares in the last quarter. ING Groep NV acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $3,500,000. Finally, Virtu KCG Holdings LLC raised its position in shares of Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares in the last quarter. Institutional investors own 20.05% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals (ARWR) Now Covered by Analysts at B. Riley” was first published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://baseballnewssource.com/markets/b-riley-begins-coverage-on-arrowhead-pharmaceuticals-arwr/1818206.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.